• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

RAPID3 Scores May Help Determine the Impact of DMARD Therapy on PsA Severity


A poster presentation from AAD 2023 explored RAPID3 scores to evaluate patient-reported outcomes in routine clinical practice therapy decisions regarding PsA.


There is a lack of evidence investigating the impact of patient-reported outcomes (PROs) monitoring in routine clinical practice, according to a poster presented at the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans, Louisiana.1 PROs are needed in clinical trials to evaluate the impact of treatment on symptom control and quality of life of patients. Study authors sought to examine the role of PROs in routine clinical practical therapy decisions among psoriatic arthritis patients (PsA) and how RAPID3 (routine assessment of patient index data 3) scores can assess the impact of disease-modifying antirheumatic drug(s) (DMARD).

Using OM1’s platform, a real-world data and AI-based health care data company, structured and unstructured data from electronic medical records and other sources were linked in a continuous method. Out of 37,301 patients from the OM1 PremiOM-PsA dataset treated by rheumatologists, fluctuations in DMARD therapy were identified. Baseline RAPID3 scores were then compared to RAPID3 scores at 90, 180, and 365 days after DMARD change.

“The conclusion was that indeed, when changing DMARD therapy in patients with PsA who were non-responding, the majority had improvement in RAPID3 scores 90 days later. As RAPID3 is an easy to administer patient reported outcome - it can be a useful tool in practice to gauge therapeutic benefit,” Stefan Weiss, MD, MHSc, MBA, study author, and managing director of dermatology at OM1 told Dermatology Times®.

Key findings from the study include:

  • 24.7% of patients treated with DMARDs reported at least one RAPID3
  • Patients with a DMARD change (n=2,722) had worse RAPID3 scores at baselinecompared to those who didn’t (4.5 v. 3.8, p<0.0001) in linear mixed models
  • RAPID3 scores reported in the 30 days pretherapy change (mean±SD=4.5±2.1) were worse than scores reported at 90 days (4.2±2.1, p<0.0001), 180 days (4.2±2.2, p<0.0001) and 365 days (4.3±2.2, p<0.0001) post-therapy change

Weiss noted that he hopes fellow clinicians will remember “administering RAPID3 to patients with PsA can be an effective way to track therapeutic progress.” Overall, Weiss and fellow study authors concluded that dermatologists treating patients with PsA should consider adding RAPID3 into their clinical practice to guide treatments.

“As the leading RWD company focused in dermatology - dermatologists can partner with OM1 to track standard clinical outcomes and patient reported outcomes with the opportunity to feed that back to them in the form of interactive dashboards and other clinical improvement tools,” Weiss concluded.


  1. Mulder K, Su Z, Stevens L, Kumparatana P, Weiss S. Patient-reported outcomes and changes in DMARD therapy among psoriatic arthritis patients treated in routine clinical practice. Presented at the 2023 American Academy of Dermatology Annual Meeting; March 17-21, 2023; New Orleans, LA. Accessed March 17, 2023. https://aad-eposters.s3.amazonaws.com/AM2023/poster/43894/Patient-reported+Outcomes+and+Changes+in+DMARD+Therapy+Among+Psoriatic+Arthritis+Patients+Treated+in+Routine+Clinical+Practice.pdf
Related Videos
© 2024 MJH Life Sciences

All rights reserved.